Newswise – Hackensack Meridian Hackensack University Medical Center has launched a new study looking at the impact of omega-3 supplements on post-COVID symptoms that persist for more than 12 weeks after initial COVID infection – also known as “long COVID”. All Hackensack meridians Health team members with long-term COVID symptoms are eligible to participate in the study.
Why study its impact on the long COVID? Your body needs omega-3 fatty acids for many functions, from muscle activity to cell growth. Omega-3 fatty acid is known to produce fewer pro-inflammatory cytokines, so increasing intake of omega-3 fatty acids through diet or supplementation could potentially decrease viral entry, promote better immune function and decrease severity in those diagnosed with COVID-19.
The study, which currently has 5 participants enrolled so far, is a double-blind randomized controlled trial, which means participants will be randomly divided into two treatment groups. The first treatment group will receive EPA + DHA, an omega-3 supplement manufactured by KD Pharma, at a dose below the U.S. Food and Drug Administration (FDA) daily dosing safety thresholds and of the American Heart Association (AHA). Participants will take three mini-capsules twice daily.
The second group will receive a placebo on the same dosing schedule as the first treatment group. Neither the researchers nor the participants will know who gets the omega-3 supplement and who gets the placebo.
“This study will help us determine the feasibility of a future grant-funded clinical trial to determine the effectiveness of omega-3 supplementation on persistent COVID symptoms compared to placebo among a larger population recovering from COVID-19. COVID-19,” said Manisha Parulekar, MD. , FACP, AGSF, CMD, Director, Division of Geriatrics and Co-Director, Center for Memory Loss and Brain Health at Hackensack University Medical Center and Associate Professor at Hackensack Meridian School of Medicine.
ABOUT HACKENSACK UNIVERSITY MEDICAL CENTER
Hackensack University Medical Center, a 771-bed nonprofit teaching and research hospital, is New Jersey’s largest provider of inpatient and outpatient services. Founded in 1888 as the first hospital in Bergen County, it was the first hospital in New Jersey and the second in the nation to become a Magnet® Recognized Hospital for Nursing Excellence. The academic flagship of Hackensack Meridian Health, the Hackensack University Medical Center campus is home to facilities such as the John Theurer Cancer Center, Heart & Vascular Hospital, and Sarkis and Siran Gabrellian Women’s and Children’s Pavilion. Recognized as one of the top 1% hospitals nationwide and #2 in New Jersey by US News and World Reports Honor Roll of “Best Hospitals” 2020-21, Hackensack University Medical Center also ranked among the top performers in Cancer Care, Cardiology and Cardiac Surgery, Gastroenterology and gastrointestinal surgery, geriatrics, nephrology, neurology and neurosurgery, orthopedics, pulmonology and urology. Hackensack University Medical Center’s comprehensive clinical research portfolio includes studies focused on precision medicine, translational medicine, immunotherapy, cell therapy, and vaccine development.